Myeloid-derived suppressor cells as a potential therapy for experimental autoimmune myasthenia gravis

Journal of Immunology

Volumn 193, Issue 5, 2014, Pages 2127-2134

  Li, Yan ^a   Tu, Zhidan ^b   Qian, Shiguang ^a   Fung, John J ^a   Markowitz, Sanford D ^c   Kusner, Linda L ^d   Kaminski, Henry J ^d   Lu, Lina ^a   Lin, Feng ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; CHOLINERGIC RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M ANTIBODY; INDUCIBLE NITRIC OXIDE SYNTHASE; PROSTAGLANDIN E2; AUTOANTIBODY; IMMUNOGLOBULIN M; NICOTINIC RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; MYELOID PROGENITOR CELL; NEUROMUSCULAR SYNAPSE; NONHUMAN; STELLATE CELL; SUPPRESSOR CELL; T LYMPHOCYTE; TREATMENT INDICATION; TREATMENT RESPONSE; ANIMAL; B LYMPHOCYTE; BONE MARROW CELL; IMMUNOLOGY; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; PATHOLOGY; TRANSPLANTATION;

ANIMALS; AUTOANTIBODIES; B-LYMPHOCYTES; DINOPROSTONE; HEPATIC STELLATE CELLS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MICE; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; MYELOID CELLS; RECEPTORS, NICOTINIC; T-LYMPHOCYTES;

EID: 84907031164     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400857     Document Type: Article

References (40)

1. Gomez, A. M., J. Van Den Broeck, K. Vrolix, S. P. Janssen, M. A. Lemmens, E. Van Der Esch, H. Duimel, P. Frederik, P. C. Molenaar, P. Martínez-Martínez, et al. 2010. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Autoimmunity 43: 353-370.
2. Conti-Fine, B. M., M. Milani, and H. J. Kaminski. 2006. Myasthenia gravis: past, present, and future. J. Clin. Invest. 116: 2843-2854.
3. Wu, B., E. Goluszko, R. Huda, E. Tuzun, and P. Christadoss. 2011. Experimental autoimmune myasthenia gravis in the mouse. Curr. Protoc. Immunol. Chapter 15: Unit 15.23.
4. Young, M. R., M. Newby, and H. T. Wepsic. 1987. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res. 47: 100-105.
5. Buessow, S. C., R. D. Paul, and D. M. Lopez. 1984. Influence of mammary tumor progression on phenotype and function of spleen and in situ lymphocytes in mice. J. Natl. Cancer Inst. 73: 249-255.
6. Ostrand-Rosenberg, S., and P. Sinha. 2009. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182: 4499-4506.
7. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
8. Nagaraj, S., A. G. Schrum, H. I. Cho, E. Celis, and D. I. Gabrilovich. 2010. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J. Immunol. 184: 3106-3116.
9. Solito, S., V. Bronte, and S. Mandruzzato. 2011. Antigen specificity of immune suppression by myeloid-derived suppressor cells. J. Leukoc. Biol. 90: 31-36.
10. Chou, H. S., C. C. Hsieh, H. R. Yang, L. Wang, Y. Arakawa, K. Brown, Q. Wu, F. Lin, M. Peters, J. J. Fung, et al. 2011. Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice. Hepatology 53: 1007-1019.
11. Hsieh, C. C., H. S. Chou, H. R. Yang, F. Lin, S. Bhatt, J. Qin, L. Wang, J. J. Fung, S. Qian, and L. Lu. 2013. The role of complement component 3 (C3) in differentiation of myeloid-derived suppressor cells. Blood 121: 1760-1768.
12. Sheng, J. R., T. Muthusamy, B. S. Prabhakar, and M. N. Meriggioli. 2011. GMCSF- induced regulatory T cells selectively inhibit anti-acetylcholine receptorspecific immune responses in experimental myasthenia gravis. J. Neuroimmunol. 240-241: 65-73.
13. Li, J., H. Qi, E. Tüzün,W. Allman,V. Yilmaz, S. S. Saini, F. Deymeer, G. Saruhan- Direskeneli, and P. Christadoss. 2009. Mannose-binding lectin pathway is not involved in myasthenia gravis pathogenesis. J. Neuroimmunol. 208: 40-45.
14. Lin, F., H. J. Kaminski, B. M. Conti-Fine, W. Wang, C. Richmonds, and M. E. Medof. 2002. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J. Clin. Invest. 110: 1269-1274.
15. Shih, T. A., M. Roederer, and M. C. Nussenzweig. 2002. Role of antigen receptor affinity in T cell-independent antibody responses in vivo. Nat. Immunol. 3: 399-406.
16. Liu, R., J. Hao, C. S. Dayao, F. D. Shi, and D. I. Campagnolo. 2009. T-bet deficiency decreases susceptibility to experimental myasthenia gravis. Exp. Neurol. 220: 366-373.
17. Qi, H., E. Tüzün, W. Allman, S. S. Saini, Z. R. Penabad, S. Pierangeli, and P. Christadoss. 2008. C5a is not involved in experimental autoimmune myasthenia gravis pathogenesis. J. Neuroimmunol. 196: 101-106.
18. Maizels, N., and A. Bothwell. 1985. The T-cell-independent immune response to the hapten NP uses a large repertoire of heavy chain genes. Cell 43: 715-720.
19. Eruslanov, E., I. Daurkin, J. Ortiz, J. Vieweg, and S. Kusmartsev. 2010. Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells. J. Leukoc. Biol. 88: 839-848.
20. Murn, J., O. Alibert, N. Wu, S. Tendil, and X. Gidrol. 2008. Prostaglandin E2 regulates B cell proliferation through a candidate tumor suppressor, Ptger4. J. Exp. Med. 205: 3091-3103.
21. Futaki, N., S. Takahashi, M. Yokoyama, I. Arai, S. Higuchi, and S. Otomo. 1994. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 47: 55-59.
22. Tai, H. H., C. M. Ensor, M. Tong, H. Zhou, and F. Yan. 2002. Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat. 68-69: 483-493.
23. Coggins, K. G., A. Latour, M. S. Nguyen, L. Audoly, T. M. Coffman, and B. H. Koller. 2002. Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus. Nat. Med. 8: 91-92.
24. Griffith, O.W., and R. G. Kilbourn. 1996. Nitric oxide synthase inhibitors: amino acids. Methods Enzymol. 268: 375-392.
25. Tenu, J. P., M. Lepoivre, C. Moali, M. Brollo, D. Mansuy, and J. L. Boucher. 1999. Effects of the new arginase inhibitor N(omega)-hydroxy-nor-Larginine on NO synthase activity in murine macrophages. Nitric Oxide 3: 427-438.
26. Collongues, N., O. Casez, A. Lacour, C. Tranchant, P. Vermersch, J. de Seze, and C. Lebrun. 2012. Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. Muscle Nerve 46: 687-691.
27. Wylam, M. E., P. M. Anderson, N. L. Kuntz, and V. Rodriguez. 2003. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J. Pediatr. 143: 674-677.
28. Stübgen, J. P. 2008. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders. J. Neuroimmunol. 204: 1-12.
29. Yoshikawa, H., K. Iwasa, K. Satoh, and M. Takamori. 1997. FK506 prevents induction of rat experimental autoimmune myasthenia gravis. J. Autoimmun. 10: 11-16.
30. Drachman, D. B., R. N. Adams, K. McIntosh, and A. Pestronk. 1985. Treatment of experimental myasthenia gravis with cyclosporin A. Clin. Immunol. Immunopathol. 34: 174-188.
31. Allison, A. C., and E. M. Eugui. 2000. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47: 85-118.
32. Haverkamp, J. M., S. A. Crist, B. D. Elzey, C. Cimen, and T. L. Ratliff. 2011. In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur. J. Immunol. 41: 749-759.
33. Yu, J., W. Du, F. Yan, Y. Wang, H. Li, S. Cao,W. Yu, C. Shen, J. Liu, and X. Ren. 2013. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J. Immunol. 190: 3783-3797.
34. Hoechst, B., L. A. Ormandy, M. Ballmaier, F. Lehner, C. Krüger, M. P. Manns, T. F. Greten, and F. Korangy. 2008. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+) Foxp3(+) T cells. Gastroenterology 135: 234-243.
35. Green, K. A., W. J. Cook, and W. R. Green. 2013. Myeloid-derived suppressor cells in murine retrovirus-induced AIDS inhibit T- and B-cell responses in vitro that are used to define the immunodeficiency. J. Virol. 87: 2058-2071.
36. Tai, H. H., H. Cho, M. Tong, and Y. Ding. 2006. NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions. Curr. Pharm. Des. 12: 955-962.
37. Hughes, D., T. Otani, P. Yang, R. A. Newman, R. K. Yantiss, N. K. Altorki, J. L. Port, M. Yan, S. D. Markowitz, M. Mazumdar, et al. 2008. NAD +-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev. Res. (Phila.) 1: 241-249.
38. Yao, C., D. Sakata, Y. Esaki, Y. Li, T. Matsuoka, K. Kuroiwa, Y. Sugimoto, and S. Narumiya. 2009. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat. Med. 15: 633-640.
39. Thompson, P. A., D. F. Jelinek, and P. E. Lipsky. 1984. Regulation of human B cell proliferation by prostaglandin E2. J. Immunol. 133: 2446-2453.
40. Serafini, P. 2010. Editorial: PGE2-producing MDSC: a role in tumor progression? J. Leukoc. Biol. 88: 827-829.